Sindbis Viral Vector E2 Protein Mutations for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Sindbis viral vectors for cancer therapy are not effective in achieving complete survival of mice with tumor-induced SCID models, despite showing promise in targeting tumor cells and reducing tumor growth, indicating a need for improved vectors with enhanced targeting and tumor reduction capabilities.
Innovation Solution
Development of new Sindbis viral vectors derived from wild-type Ar-339 Sindbis virus with specific differences in replicase and envelope proteins, including chimeric combinations of JT and Ar-339 strains, and mutation analysis of the E2 envelope protein to optimize tumor targeting, using techniques such as IVIS imaging to identify critical residues for vector efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Sindbis viral vectors are used to target tumor cells, then tumor growth is reduced, but complete survival of mice is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the envelope protein sequence of the Sindbis virus vector. Specifically, the E2 envelope protein was mutated to alter its binding affinity and specificity for tumor cell receptors. This parameter change in the viral vector's molecular structure enabled enhanced tumor targeting capability, resolving the contradiction between tumor reduction efficacy and survival rate by making the vector more effective at its primary function.
2Measurement precision
If Sindbis vectors with high affinity for HALR are used, then tumor cell targeting is improved, but vector efficiency needs enhancement
Solution Approach 1:
The patent applies local quality by introducing specific point mutations in the E2 envelope protein region that is responsible for HALR binding. Rather than modifying the entire vector, the invention focuses on optimizing the local binding domain to enhance both targeting accuracy and overall vector efficiency. This localized modification approach allowed simultaneous improvement of both parameters.
3Measurement precision
If E2 envelope protein mutations are introduced to enhance targeting, then tumor targeting ability is improved, but vector complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the envelope protein modification into discrete, targeted amino acid substitutions rather than comprehensive restructuring. The E2 protein was modified through specific point mutations (such as K70E, E166K, V251L) that independently contribute to enhanced targeting. This segmented approach to protein engineering improved tumor targeting while minimizing the increase in overall vector complexity.
Data Source
AI summary
Disclosed herein are new defective Sindbis viral vectors made from a novel Helper plasmid, with differences in envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are vectors produced using the plasmid, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.